Finn
JNJ Healthcare · Large cap · Pharma · MedTech · Thesis updated October 18, 2026

Strong drug sales offset medical device slowdowns and generic pressure

01 Running thesis

A patent cliff expands while device growth stalls

Johnson & Johnson is proving the main bull case for its drug business. STELARA is falling hard after cheaper copies entered the market, but the rest of the drug portfolio is growing fast enough to offset the damage. In Q3 2026, the Innovative Medicine segment grew almost 8 percent operationally. Oncology drugs and newer immunology treatments like TREMFYA are taking dominant market share.

However, the medical device business is now a worry. Abiomed was supposed to be a key growth engine in cardiovascular devices, but sales fell again in Q3. Doctors are using the product more carefully. The company also faced international device headwinds from pricing changes in China and delayed orders in the Middle East. MedTech growth fell well short of internal targets.

Finn's view is balanced. JNJ has real growth engines in pharmaceuticals and a new surgical robot named OTTAVA that just won clearance. It also proposed a massive 5.5 billion dollar settlement to finally resolve its talc litigation overhang. But with medical devices struggling and generic drug competition expanding, the stock still has to earn its price.

Oct 2026→Q3 2026 showed a clear split. Innovative Medicine grew strongly led by TREMFYA, while MedTech missed expectations due to Abiomed and international headwinds. The company also proposed a 5.5 billion dollar talc settlement.
Jul 2026→The Q2 2026 10-Q disclosed new generic competition for OPSUMIT and SIMPONI, expanding the patent cliff. It also detailed a new 650 million dollar supply chain restructuring program.
Jul 2026→Q2 2026 showed JNJ can offset a 55.7 percent STELARA decline with double-digit growth outside that drug. The offset was partly balanced by a new concern as Abiomed sales fell 2 percent.
Apr 2026▲Q1 2026 strengthened the thesis. Worldwide operational sales grew 6.4 percent despite a 5.4 percent STELARA headwind, helped by oncology and cardiovascular growth.
Feb 2026▲The 2025 Form 10-K showed strong growth in oncology and cardiovascular devices. It also kept talc litigation in focus after a large reserve reversal did not remove the underlying legal risk.
Oct 2025▲Q3 2025 showed 5.4 percent operational growth even with a 6.4 percent STELARA headwind. JNJ also announced plans to separate Orthopaedics within 18 to 24 months.
Jul 2025→Q2 2025 confirmed the basic tradeoff. STELARA pressure worsened, but oncology and cardiovascular growth were strong enough to keep overall growth positive.
Apr 2025▲Q1 2025 gave the first clear look at STELARA biosimilar pressure. JNJ still delivered 4.2 percent operational growth, led by oncology and cardiovascular devices.
02 Business model

Patents, hospitals, and surgical suites

Johnson & Johnson makes money in two main ways. Innovative Medicine sells patented prescription drugs. MedTech sells devices used by surgeons, heart doctors, eye doctors, and hospitals.

The drug business is highly profitable while a product has patent protection. The risk is that sales fall fast when cheaper copies arrive, as STELARA, SIMPONI, and OPSUMIT show. That is why JNJ needs new launches like TREMFYA and ICOTYDE to keep replacing older products.

The device business depends on hospital budgets, doctor training, and procedure volumes. A single clinical study can change behavior quickly. Abiomed's recent struggles show that MedTech is exposed to sudden shifts in doctor confidence.

JNJ benefits from massive research spending, global sales reach, and long relationships with healthcare providers. Those strengths are real, but they do not remove legal risk, pricing pressure, or product cycle risk.

03 Product portfolio

The products that drive the future

Growth engine

DARZALEX

DARZALEX is the largest product for JNJ and treats multiple myeloma, a blood cancer. It drives significant growth for the company.

Cash cow

STELARA, SIMPONI, and OPSUMIT

These legacy drugs were major profit pools but now face cheaper generic or biosimilar competition, driving steep sales declines.

Growth engine

TREMFYA

TREMFYA is now the main immunology growth story. It recently took the top share for new prescriptions in key bowel disease markets.

Growth engine

Abiomed

This cardiovascular device franchise is under pressure after a neutral trial caused doctors to change their usage habits.

Option

OTTAVA

This new robotic surgical system just won regulatory clearance, giving JNJ a path into a highly profitable surgical market.

Steady

Orthopaedics

Orthopaedics sells joint implants and related surgical products. JNJ plans to spin this business off to sharpen its growth focus.

04 Business segments

Two businesses, one bigger drug engine

Innovative Medicine66%modest
MedTech34%flat

Segment mix uses Q3 2026 sales. Innovative Medicine generated 16.8 billion dollars and MedTech generated 8.6 billion dollars.

05 Risk factors

What could break the thesis

Generics fall faster than replacements grow

High impact · High odds

STELARA biosimilars are already hurting sales, and SIMPONI and OPSUMIT just lost exclusivity. The key question is whether oncology and new immunology drugs can keep offsetting multiple declining legacy products.

We watchQuarterly decline rates for STELARA, SIMPONI, and OPSUMIT, and total company growth excluding them.

Abiomed weakness becomes structural

High impact · Medium odds

Abiomed sales fell 1.5 percent in Q3 2026 after doctors reacted to a neutral UK trial. Management called the effect behavioral, but doctor behavior can stick. If growth does not recover before the PROTECT IV readout in 2027, a key MedTech growth pillar may be stalled.

We watchAbiomed procedure volumes, U.S. utilization, and the 2027 PROTECT IV clinical trial results.

Talc settlement fails to reach the threshold

High impact · Medium odds

JNJ proposed a 5.5 billion dollar resolution for ovarian talc claims. However, this agreement requires 95 percent of claimants to opt in. If that threshold is missed, the litigation overhang remains active and costly.

We watchParticipation rates in the proposed talc settlement and any updates on the 95 percent threshold.

International device markets stall

Medium impact · High odds

The MedTech business faces international headwinds like volume-based pricing in China and tender delays in the Middle East. If these issues are structural rather than temporary, device growth will struggle.

We watchManagement commentary on China VBP impacts and international surgical volumes.

Orthopaedics separation disappoints

Medium impact · Medium odds

JNJ plans to separate Orthopaedics via a spin-off. The move could sharpen the remaining company's growth profile, but it also brings execution risk. Investors still need details on debt, margins, and the growth profile of the separated company.

We watchSeparation filings, timing updates, debt allocation, and standalone margin targets.
06 Quick answers

In one breath

What does Johnson & Johnson do now?

After separating consumer health, JNJ is mainly a prescription drug and medical device company. Its two segments are Innovative Medicine and MedTech.

Why are STELARA, SIMPONI, and OPSUMIT losing sales?

These drugs face biosimilar or generic competition, which means cheaper versions can take share. JNJ must replace that lost sales base with newer drugs.

Why does Abiomed matter?

Abiomed is a major part of JNJ's cardiovascular device growth plan. Its recent sales declines raised questions about whether doctor caution is temporary or lasting.

Is Johnson & Johnson cheap?

Finn's valuation score is below the middle of the range, so the price is not an obvious bargain. The company has quality assets, but investors still need proof that growth can keep compounding.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
October 18, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Johnson & Johnson Q2 2026 Form 10-Q
  2. Johnson & Johnson Q3 2026 Earnings Transcript
08 Explore the industry

Comparable Drug Manufacturers - General companies

Companies near Johnson & Johnson in Finn's Drug Manufacturers - General industry ranking.

Get started with Finn today